Live on location at the Dana-Faber Cancer Institute, Patient Power PR Contributor and CLL patient Michele Nadeem-Baker takes us inside the infusion room where she is currently undergoing treatment.  She is participating in the first-ever clinical trial where ibrutinib (Imbuvica) is combined with FCR to achieve MRD negativity (total cure).  Michele explains the parameters of this Phase II trial and shares her personal insights as a patient.  Listen for Michele’s challenge as she encourages all cancer patients to “Be brave and bold.”